
Anthony Carpanzano, Director of R&D at JRS Pharma, discussed ongoing formulation challenges and trends.

Anthony Carpanzano, Director of R&D at JRS Pharma, discussed ongoing formulation challenges and trends.


The animal origin-free (AOF) trend in bioprocessing has taken a while to reach microbial bioproduction. In this podcast, we explore the reasons behind this and delve into how AOF products are impacting the future of biopharmaceutical manufacturing. We also discuss the first chemically defined microbial medium—the Gibco™ Bacto™ CD Supreme Fermentation Production Medium (FPM). Hydrolysate-free and AOF, this dry powder medium was specially designed to support high-cell-density cultures of E. Coli. Listen to bioprocessing experts and discover more.

This webinar highlights the development of the first chemically defined microbial medium. Designed to simplify workflows and achieve high density cultures, the Gibco™ Bacto™ CD Supreme supports advancements in therapeutics, gene therapy, and vaccine development. Discover data shared by experts and explore how you can improve process productivity and reduce risks.




Pharmaceutical Technology editors interview an automation expert from Automata on the benefits of automating entire workflows in analytics versus automating only specific pieces of equipment or only certain processes.

The first segment of this five-part PPD Tech Talk series on A CMC Roadmap for Cell and Gene Therapies, Katherine Hanson, Ph.D., associate director at PPD Laboratory services, GMP Lab, discusses regulatory considerations for cell and gene therapies.

The second segment of this five-part PPD Tech Talk series Jie Ding, director, and Derek Wood, associate director, at PPD Laboratory services, GMP Lab, discuss pre-requisites such as LC-MS and extractables and leachables (E&L) implications.

In the third part of this five part series, Marc Wolman, labs manager, biopharmaceutical at PPD Laboratory services, GMP Lab, & Jurgen Hannig, senior principal scientist at PPD Laboratory services talk about new analytical tools for cell & gene therapies.

In the fourth part of this five-part series, Ryan Ellefson, director of lab informatics & data analytics, at PPD Laboratory services GMP Lab, and Benjamin Ziehr, senior group leader at PPD Laboratory services GMP Cell Lab, discuss data automation.

In the final segment of this five-part series, A CMC Roadmap to Cell and Gene Therapies, Derrick McVicker, group leader, at PPD Laboratory services, GMP Lab, discusses the transfer of bioanalytical methods to GMP Lab.

An interview with Tom Sellig the Chief Executive Officer of Adare Pharma Solutions at the CPHI Conference in Frankfurt, Germany.

This is the first segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts Olivia Aspite and Bryan Neth of PPD®, part of Thermo Fisher Scientific.

This is the second segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts Chris Clendening and Tim Rich.

This is the final segment of this three-part PPD Tech Talk series on Improving Clinical Trials with Innovative Data Solutions featuring experts John Maier and Renay Perry of PPD®, part of Thermo Fisher Scientific.


This video is an interview with Jon Brice, Vice President of Business Development at Asymchem at the AAPS Conference in Boston, Massachusetts.




Learn about the benefits of tailored active pharmaceutical ingredient [API] nanoparticles in this webinar with Christopher P. Worrall, Ph.D. This presentation looks at how API nanoparticles enable patient-centric therapies and benefit many dosage forms, as well as how industry collaborations drive novel drug delivery approaches.

Learn how TargTex partners with Nanoform to produce therapies for Glioblastoma patients. This process includes identifying novel targets with small molecules, utilizing Nanoform technology to increase the active pharmaceutical ingredient [API] concentration, and improving treatment stability to move the drug to clinical development.


Pharmaceutical Technology editors interview oral solid dosage development experts from Syntegon and Colorcon, with discussions centered on continuous OSD production, containment safety, and authentication at the dose level.

Pharmaceutical Technology editors interview aseptic and sterilization experts from Watson-Marlow Fluid Technology Solutions and Cherwell—diving into sterilization, aseptic processing, and the revised EU GMP Annex 1 guidance.

What does Ascendia do? What sets Ascendia apart from its competitors? What is Ascendia's company culture like?

Pharmaceutical Technology speaks with Jennifer Hurst, senior director at MasterControl.

In this exclusive Drug Digest video, experts from Roche and MilliporeSigma divulge factors that could influence an organization to pursue specific biomolecules for development.